Current/ Expected Orderbook/ Pending Orders?

As per the transcript on page 7, the number of orders can be estimated by dividing revenue by ticket size: FY26 revenue was ₹200 crores and ticket size around ₹3,250, implying approximately 6.15 million orders. Current business run rate is around ₹225 crores, expecting growth to ₹300 crores in FY27 with new initiatives contributing additional ₹50-₹55 crores. Growth drivers include subsidiaries, US operations, AI improvements, nutraceuticals via Ajooni Life Sciences, and geographic expansion in under-penetrated markets. Company is focusing on deepening reach from strong pockets like Tamil

Any current/future new fundraising through debt or equity?

The company plans to fund any shortfall in working capital primarily through debt. Currently, there is no plan for further equity dilution or raising funds through equity. The company has raised around ₹45 crores in capital, which will support the first phase of hospital expansion. Cash generation from hospitals and the company’s core business is expected to fund the second phase of hospital growth. Overall, debt is the preferred mode of additional fundraising if required, with no immediate plans for equity fundraising.

Any current/future capex/capital investment/strategic investment?

Current capex includes upgrading existing manufacturing facility (capsule and powder units) with an investment of around ₹1-1.25 crore. Hospital bed setup capex is estimated at ₹7-8 lakhs per bed, with ₹4 lakhs considered as fixed asset cost and the balance as working capital. For the planned 1000 beds, estimated capex is around ₹40 crore (₹4 lakh per bed). Capital for initial phases of hospital expansion raised with ₹45 crore in the bank to build the first phase. Subsequent phases to be funded through internal cash generation and possibly debt; no current plans for further equity dilution. No

Future growth expectations in sales/revenue/volumes?

FY 27 product revenue target: ₹300 crores, driven by: - Current run rate at ₹225 crores with expected 25% growth in current business. - Subsidiaries contributing ~₹22 crores. - US operations adding ₹10-15 crores. - AI efficiencies and nutraceuticals (Ajooni Life Sciences) adding ~₹20 crores. FY 28 product revenue target: ₹500 crores, fueled by: - New high-ticket products. - Better product margins. - Controlled advertisement spend. - Increased ticket size and scaling sales. Hospital business expansion: - 300 beds target by end FY 27, starting simultaneous set-up of 4 facilit

Future growth expectations in earnings/operating earnings/profits/EPS?

FY26 PAT margin grew from 6% to 8.5% with revenue growth from 160 to 200 crore. FY27 target: Revenue growth from 200 to 300 crore; PAT margin targeted at 11-12%. FY28 target: Revenue expected to cross 500 crore with blended margin including hospital business reaching 18-20%. Hospital business at 60% occupancy expected to deliver 30-35% margin; higher occupancy exponentially increases margins. Operating leverage from fixed costs expected to improve profitability as revenues scale. AI optimization is improving ROI by 4-5%, expected to further enhance margins over time. Subsidiaries expected to g

IN US

Sale is live|00:00:00left today

Sat Kartar Life LtdQ1 FY27Pharmaceuticals & Biotechnology

Sat Kartar Life Ltd Q1 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹127P/E: 22.4Market Cap: ₹308 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

Yes

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→FY 27 product revenue target: ₹300 crores, driven by:
→ - Current run rate at ₹225 crores with expected 25% growth in current business.
→ - Subsidiaries contributing ~₹22 crores.
→ - US operations adding ₹10-15 crores.
→ - AI efficiencies and nutraceuticals (Ajooni Life Sciences) adding ~₹20 crores.
→FY 28 product revenue target: ₹500 crores, fueled by:
→ - New high-ticket products.
→ - Better product margins.
→ - Controlled advertisement spend.
→ - Increased ticket size and scaling sales.
→Hospital business expansion:
→ - 300 beds target by end FY 27, starting simultaneous set-up of 4 facilities.
→ - Plan to expand to 1000 beds by FY 28.
→ - Hospital margins expected at 30-35% at 60% occupancy.
→ - Blended margin (product + hospital) expected at 18-20% by H1 FY 28.
→Growth to come from wider geographic penetration beyond strongholds (TN, UP).

Margin guidance

Category 1

→FY26 PAT margin grew from 6% to 8.5% with revenue growth from 160 to 200 crore.
→FY27 target: Revenue growth from 200 to 300 crore; PAT margin targeted at 11-12%.
→FY28 target: Revenue expected to cross 500 crore with blended margin including hospital business reaching 18-20%.
→Hospital business at 60% occupancy expected to deliver 30-35% margin; higher occupancy exponentially increases margins.
→Operating leverage from fixed costs expected to improve profitability as revenues scale.
→AI optimization is improving ROI by 4-5%, expected to further enhance margins over time.
→Subsidiaries expected to grow from ₹1.2 crores revenue in FY26 to 25-30 crore in FY27, supporting overall profit growth.
→No immediate plans for equity dilution; future funding for expansion may come from debt.
→Overall, significant margin expansion and profit growth planned via scaling products and hospital beds, with EPS expected to benefit accordingly.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company plans to fund any shortfall in working capital primarily through debt.
→Currently, there is no plan for further equity dilution or raising funds through equity.
→The company has raised around ₹45 crores in capital, which will support the first phase of hospital expansion.
→Cash generation from hospitals and the company’s core business is expected to fund the second phase of hospital growth.
→Overall, debt is the preferred mode of additional fundraising if required, with no immediate plans for equity fundraising.

Order book

Yes

→As per the transcript on page 7, the number of orders can be estimated by dividing revenue by ticket size: FY26 revenue was ₹200 crores and ticket size around ₹3,250, implying approximately 6.15 million orders.
→Current business run rate is around ₹225 crores, expecting growth to ₹300 crores in FY27 with new initiatives contributing additional ₹50-₹55 crores.
→Growth drivers include subsidiaries, US operations, AI improvements, nutraceuticals via Ajooni Life Sciences, and geographic expansion in under-penetrated markets.
→Company is focusing on deepening reach from strong pockets like Tamil Nadu, North Uttar Pradesh, Madhya Pradesh, and Maharashtra, aiming to increase order volume through wider pan-India presence.
→Repeat patient orders are stable around 25-26%, supporting recurring order inflow.

Capex plans

Yes

→Current capex includes upgrading existing manufacturing facility (capsule and powder units) with an investment of around ₹1-1.25 crore.
→Hospital bed setup capex is estimated at ₹7-8 lakhs per bed, with ₹4 lakhs considered as fixed asset cost and the balance as working capital.
→For the planned 1000 beds, estimated capex is around ₹40 crore (₹4 lakh per bed).
→Capital for initial phases of hospital expansion raised with ₹45 crore in the bank to build the first phase.
→Subsequent phases to be funded through internal cash generation and possibly debt; no current plans for further equity dilution.
→No plan to produce all products in-house; focus on scaling with collaborations and selective manufacturing upgrades.
→US subsidiary investment awaiting RBI approval, expected operational soon, no capital cited beyond standard overseas direct investment processes.

How does Sat Kartar Life Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Sat Kartar Life Ltd

Rev 2Mar 1

See full Pharmaceuticals & Biotechnology sector rankings